Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2
Diagnosis, Therapeutic Targets, and Molecular Mechanisms
- 1st Edition - April 1, 2022
- Editors: Ganji Purnachandra Nagaraju, Ramakrishna Vadde
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 8 8 0 7 - 0
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 9 3 6 5 - 4
Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume Two: Diagnosis, Therapeutic Targets and Molecular Mechanisms for Hepatocellular Carci… Read more
Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume Two: Diagnosis, Therapeutic Targets and Molecular Mechanisms for Hepatocellular Carcinoma Progression provides comprehensive information about ongoing research and clinical data surrounding liver cancer. The book presents detailed descriptions about diagnostics and therapeutic options for easy understanding, with a focus on precision medicine approaches to improve treatment outcomes. The volume discusses topics such as computational approaches for identification of biomarkers, enzymes and pathways of HCC, circulating and epigenetic biomarkers, drug resistance, metabolic pathways, and small molecule-target therapies. In addition, it discusses immunotherapies, immune check point inhibitors and nanotechnology-based therapies.
This book is a valuable resource for cancer researchers, oncologists, graduate students, hepathologists and members of biomedical research who need to understand more about liver cancer to apply in their research work or clinical setting.
- Provides detailed information on traditional and novel diagnostic tools for hepatocellular carcinoma
- Discusses promising targeted therapies, both available and in development, explaining the best option to use for specific cases
- Brings recent findings in immunotherapies, immune checkpoint inhibitors and nanotechnology-based therapeutic approaches for treatment of HCC
Cancer researchers, oncologists. Medical doctors, hepathologists, graduate students
1. Hepatocellular carcinoma diagnosis2. Computational analysis of prognosisrelated genes in liver cancer3. Computational approaches to identify biomarkers, enzymes, and pathways of hepatocellular carcinoma4. Ribonucleic acid sequence analysis in deciphering hepatocellular carcinoma5. Hepatocarcinogenesis and the role of next-generation sequencing in liver cancer6. Liver cancer: the tumor microenvironment and associated pathways7. Metabolic pathway-based target therapy to hepatocellular carcinoma: a computational approach8. Targeting ion channels in hepatic cancer9. Tyrosine kinases: their role in hepatocellular carcinoma10. Role of transcription factors in hepatocellular carcinoma11. Modulatory act of diverse transcriptional factors in liver carcinoma12. Association of specificity protein 1 with hepatocellular carcinoma13. Promising biomarkers for liver cancer14. Molecular signaling and its role in drug resistance in hepatocellular carcinomas15. Multidrug resistance, a major obstacle in hepatocellular carcinoma treatment: challenges and future perspectives16. Proliferative signaling pathways in hepatocellular carcinoma17. Targeting angiogenesis in hepatocellular carcinoma18. Conventional and novel biomarkers for the diagnosis and prognosis of liver cancer19. Updates on the staging and treatment of hepatocellular carcinoma20. ROS-mediated pathways: potential role in hepatocellular carcinoma biology and therapy21. Dysregulated cell-signaling pathways in hepatocellular carcinoma: causes and therapeutic options22. LKB1/STK11-mediated signal transduction in hepatocellular carcinoma
- Edition: 1
- Published: April 1, 2022
- Language: English
GN
Ganji Purnachandra Nagaraju
Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. He received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational projects related to gastrointestinal malignancies. He has published over 100 research papers in highly reputed international journals and has presented more than 50 abstracts at various national and international conferences. Dr. Nagaraju is author and editor of several published books in Elsevier and Springer Nature. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR).
Affiliations and expertise
Assistant Professor, School of Medicine, Division of Hematology and Oncology, University of Alabama, Birmingham, AL, USARV
Ramakrishna Vadde
Dr Vadde Ramakrishna is Assistant Professor at the Department of Biotechnology & Bioinformatics, Yogi Vemana University, India. He obtained his MSc and PhD, both in Biochemistry, from Sri Krishnadevaraya University, Anantapur, India, and subsequently received a DBT CREST Award to pursue advanced training in cancer research at Pennsylvania State University and Colorado State University, USA. He is currently using in vitro, in vivo and in silico models to explore the role of dietary bioactive compounds in both the development and prevention of cancer through a ‘polypharmacology’ approach. He has published over 90 research papers in prominent international journals and has presented more than 40 papers at national and international conferences. He serves as an editorial board member for several international journals, and is an Associate Fellow of Andhra Pradesh Academy of Sciences.
Affiliations and expertise
Assistant Professor, Department of Biotechnology and Bioinformatics, Yogi Vemana University, IndiaRead Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2 on ScienceDirect